Abstract Library

#3947 Heterogeneity of multiple pancreatic neuroendocrine tumors identified by 68Ga-DOTANOC and 68Ga-exendin-4 PET/CT in a patient with endogenous hyperinsulinemic hypoglycaemia and multiple endocrine neoplasia 1

Introduction: Insulinomas are the most frequent functional neuroendocrine tumors of pancreas cause endogenous hyperinsulinemic hypoglycemia (EHH). In about 10% cases, insulinomas are associated with multiple endocrine neoplasia 1 (MEN1).

Conference:

Presenting Author: Xu J

Authors: Xu X, Xu X, Liang Y, Zhang M, Chen J,

Keywords: MEN1, insulinoma, 68Ga-DOTANOC, 68Ga-exendin-4, PET/CT,

#2737 Identification of a Novel MAFA Missense Mutation Causing Familial Insulinomatosis

Introduction: Insulinomatosis is a rare pancreatic disease characterized by an adult-onset condition of recurrent hyperinsulinemic hypoglycemia caused by multiple insulin-secreting neuroendocrine tumors.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Fottner C

Authors: Fottner C, Sollfrank S, Ghiasi M, Ferrata M, Schad A,

Keywords: Insulinomatosis, Insulinoma, hyperinsulinemic hypoglycemia, MAFA,

#2249 Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma

Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Davi' M

Authors: Zambon G, Cosaro E, Cingarlini S, Trombetta M, Landoni L,

Keywords: pasireotide, malignant insulinoma, hypoglycemia,

#1709 68Ga-NODAGA-exendin-4 PET/CT for the Localization of Insulinomas: Preliminary Data from a Prospective Multicenter Imaging Study.

Introduction: Insulinomas are usually small, single tumors. Precise preoperative localization of the tumor is essential. Imaging techniques like CT and MRI have limited sensitivity and also somatostatin receptor (SSTR) imaging is not specific. Exendin specifically binds the GLP-1 receptor (GLP-1R), which is markedly upregulated in insulinomas. 68Ga-DOTA-exendin-4 PET/CT has been shown to be feasible in detecting insulinomas. Replacing DOTA by NODAGA ensures higher specific activities. We propose 68Ga-NODAGA-exendin-4 PET/CT as a promising new method for improved localization of insulinomas.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Boss M

Authors: Boss M, Buitinga M, Brom M, Wild D, Prasad V,

Keywords: Insulinoma, PET, exendin,

#1057 Localisation of Insulinoma and Beta-Cells: Comparison of Glucagon-Like Peptide-1 Receptor (GLP1-R) SPECT/CT, PET/CT and MRI. Preliminary Results of a Prospective Clinical Study.

Introduction: SPECT/CT imaging with GLP1-R specific radiotracers like 111In-DOTA-exendin-4 have already proved to be a useful tool for the preoperative localisation of insulinomas. PET/CT has several advantages over SPECT/CT: lower radiation exposure, less time consumption and higher spatial resolution.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Rottenburger C, Antwi K, Heye T, Fani M, Nicolas G,

Keywords: Insulinoma, Nesidioblastosis, Glucagon-like Peptide-1 Receptor, PET/CT, SPECT/CT,